trending Market Intelligence /marketintelligence/en/news-insights/trending/zeCpvZ1nML7obyVxPytEYA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Generex merging NuGenerex with public company to complete planned spinout

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Generex merging NuGenerex with public company to complete planned spinout

Generex Biotechnology Corp. is merging its subsidiary NuGenerex Immuno-Oncology with a public company to complete a planned spinout.

Miramar, Fla.-based Generex expects to list the spinout on a public exchange by the end of November. The public company was not named in an Oct. 15 press release.

The merger is part of Generex's go-public strategy to gain value from the Ii-Key technology and AE37 immunotherapeutic vaccine program. Generex announced plans to spin out the NuGenerex subsidiary into a separate publicly traded company in January.

Generex in June signed a letter of intent to merge NuGenerex Immuno-Oncology with Lubbock, Texas-based private company Kiromic LLC in an all-stock transaction.

NuGenerex Immuno-Oncology, which is focused on developing immunotherapies to treat cancer, infectious diseases and autoimmune disorders, is currently conducting a phase 2 study to determine the recommended dose for AE37 Peptide Vaccine in combination with Merck & Co. Inc.'s Keytruda for the treatment of patients with advanced triple-negative breast cancer.